Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics presented new findings at the AACR-NCI-EORTC conference, demonstrating the anti-tumor activity of their selective A2B receptor antagonist TT-4 in mesothelioma models, with plans for first-patient dosing in Q1 2026 [1][4][10] Group 1: Research Findings - The study provides evidence that selective adenosine A2B receptor inhibition has a direct anti-tumor effect in mesothelioma cells, reducing PD-L1 expression and pCREB levels, and modulating YAP signaling [1][2][3] - In preclinical models, TT-4 showed superior monotherapy activity compared to anti-PD-1, and the combination of TT-4 with anti-PD-1 further enhanced tumor control and immune infiltration [2][3] - In human mesothelioma spheroid systems, hypoxia-linked adenosine signaling was found to increase tumor growth and PD-L1 expression, while TT-4 effectively reduced cell growth and PD-L1 protein levels [3] Group 2: Clinical Development - TT-4 is advancing towards first-patient dosing scheduled for Q1 2026, with the current data supporting its clinical translation [4][10] - The clinical program is focused on targeting known checkpoint resistance pathways to improve treatment responses and patient quality of life [9][10] Group 3: Company Overview - AlphaTON Capital is a digital asset treasury company that also engages in drug development, focusing on oncology and immunotherapy assets [6][9] - Cyncado Therapeutics is developing small molecule adenosine receptor antagonists, with TT-4 being the lead program aimed at overcoming immune suppression in oncology [10]